Return to search

Exai Bio snags $67.5m Series A

Exai Bio, a next-generation liquid biopsy company, has secured $67.5 million in Series A financing.

Exai Bio, a next-generation liquid biopsy company, has secured $67.5 million in Series A financing. Section 32 and Casdin Capital led the round with participation from Two Sigma Ventures.

Source: Press Release